NEW YORK, Oct. 28, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Adeptus Health Inc. (“Adeptus” or the “Company”) (NYSE:ADPT) in the United States District Court for the Eastern District of Texas on behalf of purchasers of common stock of Adeptus pursuant and/or traceable to the Company’s secondary public offering (the “SPO”) on or about July 31, 2015, or purchasers of common shares between April 23, 2015 and November 16, 2015, inclusive (the “Class Period”).
According to the Complaint, Defendants made material false and/or misleading information and/or failed to disclose that (1) the Company engaged in widespread predatory billing practices, particularly with respect to lower acuity level patients; (2) Adeptus’ predatory billing practices subjected the Company to numerous known but undisclosed risks, such as financial risks, reputational risks, risks associated with improper financial reporting, civil or criminal sanctions, and even exclusion from federal and state healthcare programs; (3) the Company’s financial statements were not prepared in conformity with Generally Accepted Accounting Principles; (4) contrary to the Company’s representations about its practice of referring lower acuity patients to urgent care facilities, Adeptus routinely treated lower acuity patients and excessively billed them for services; and (5) as a result of the above, Adeptus lacked a reasonable basis for its statements about its business and future financial prospects at all relevant times.
On November 17, 2015, KUSA, an NBC-affiliated television station located in Denver, Colorado, aired an investigative report about the predatory billing practices at Adeptus’ Colorado First Choice emergency rooms. When this news was announced, shares of Adeptus fell in value, causing investors harm.
Investors who purchased or otherwise acquired shares on or about July 31, 2015 when the secondary public offering was made or purchased or otherwise acquired shares during the Class Period should contact the Firm prior to the December 27, 2016 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 



